{"id":2181,"date":"2024-01-23T00:00:00","date_gmt":"2024-01-23T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2181"},"modified":"2024-01-23T00:00:00","modified_gmt":"2024-01-23T00:00:00","slug":"centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/","title":{"rendered":"CENTOGENE i Fundacja Michaela J. Foxa og\u0142aszaj\u0105 projekt badawczy maj\u0105cy na celu weryfikacj\u0119 genetycznych czynnik\u00f3w ryzyka choroby Parkinsona za pomoc\u0105 multiomiki"},"content":{"rendered":"

Collaboration to accelerate research to determine role of GBA gene<\/em><\/h2>\n

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, January 23, 2024 (GLOBE NEWSWIRE) \u2013<\/strong> Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF), a non-profit organization dedicated to finding a cure for Parkinson\u2019s disease (PD), today announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA<\/em> (glucosylceramidase beta) gene.<\/p>\n

PD is a devastating neurodegenerative disease affecting over 10 million people worldwide, with many cases being linked to genetic factors. Recent research has identified the GBA<\/em> gene as a significant genetic risk factor for PD, which could shed new light on potential biological pathways for the development of effective therapies.<\/p>\n

The research project will leverage CENTOGENE\u2019s expertise in rare genetic and neurodegenerative diseases, drawing on diverse multiomic data in the CENTOGENE Biodatabank. The biodatabank currently contains more than 800,000 patients representing over 120 highly diverse countries, including over 15,000 Parkinson\u2019s disease datasets from the Company\u2019s Badanie ROPAD<\/a>, the world\u2019s largest observational study on PD genetics. In working with MJFF, the aim of the research is to establish a deeper understanding of the relationship between specific GBA<\/em> gene variants and PD.<\/p>\n

\u201cUnderstanding the different factors that actually cause Parkinson\u2019s disease are critical to advancing treatments and ultimately finding a cure,\u201d said Shalini Padmanabhan, Vice President, Discovery & Translational Research at The Michael J. Fox Foundation for Parkinson\u2019s Research. \u201cThis project with CENTOGENE will play a pivotal role in our global efforts to better understand the genetic factors of Parkinson’s, leveraging their robust multiomic datasets that they have built over the past 15 years. We are committed to working together to truly drive the most comprehensive understanding of this disease and accelerate the development of life-saving treatments for patients worldwide.\u201d<\/p>\n

\u201cThe Michael J. Fox Foundation is an inspirational leader in Parkinson\u2019s disease research. By working with them, we aim to accelerate research into specific risk factors that may help us better diagnose, understand, and treat this debilitating disease, which affects several million patients worldwide,\u201d said Prof. Peter Bauer, Chief Medical & Genomic Officer at CENTOGENE. \u201cBy combining MJFF\u2019s extensive expertise and resources with our deep understanding of the links between rare and neurodegenerative diseases, we will be able to generate pivotal multiomic insights into the role of specific variants in the GBA gene. By providing a more complete understanding of the way that the GBA gene interacts with multiple biological pathways, we can elucidate targets that can be used to develop more precise disease-modifying therapeutics for Parkinson\u2019s patients in the future.\u201d<\/p>\n

About GBA<\/em>-Associated Parkinson\u2019s Disease<\/h3>\n

GBA<\/em>-Associated Parkinson’s disease (PD) is characterized by specific variants in the GBA<\/em> (glucosylceramidase beta) gene and has been identified as one of the most common genetic risk factors for PD. Variants in the GBA<\/em> gene impair the body’s ability to break down certain fats, leading to a buildup of harmful substances in nerve cells. This accumulation, as well as potentially other independent consequences of GBA<\/em> dysfunction, can contribute to the development of PD symptoms, which resemble the motor symptoms of idiopathic PD, such as tremors, stiffness, and bradykinesia. Recognizing the connection between GBA<\/em> variants and PD is crucial for both diagnosis and potential targeted therapies, emphasizing the importance of ongoing research and clinical investigations in this area, as there’s currently no cure for PD.<\/p>\n

O firmie CENTOGENE<\/h3>\n

Misj\u0105 CENTOGENE jest dostarczanie pacjentom, lekarzom i firmom farmaceutycznym opartych na danych, zmieniaj\u0105cych \u017cycie odpowiedzi na pytania dotycz\u0105ce chor\u00f3b rzadkich i neurodegeneracyjnych. Integrujemy technologie multiomiczne z baz\u0105 danych CENTOGENE Biodatabank, zapewniaj\u0105c analiz\u0119 wielowymiarow\u0105, kt\u00f3ra b\u0119dzie stanowi\u0107 punkt odniesienia dla kolejnej generacji medycyny precyzyjnej. Nasze unikalne podej\u015bcie umo\u017cliwia szybk\u0105 i wiarygodn\u0105 diagnoz\u0119 pacjent\u00f3w, wspiera lekarzy w lepszym zrozumieniu stan\u00f3w chorobowych oraz przyspiesza i ogranicza ryzyko zwi\u0105zane z odkrywaniem, rozwojem i komercjalizacj\u0105 ukierunkowanych lek\u00f3w farmaceutycznych.<\/p>\n

Od momentu powstania w 2006 roku, CENTOGENE oferuje szybk\u0105 i wiarygodn\u0105 diagnostyk\u0119, buduj\u0105c sie\u0107 oko\u0142o 30 000 aktywnych lekarzy. Nasze multiomiczne laboratoria referencyjne w Niemczech, posiadaj\u0105ce certyfikaty ISO, CAP i CLIA, wykorzystuj\u0105 zestawy danych fenomicznych, genomicznych, transkryptomicznych, epigenomicznych, proteomicznych i metabolomicznych. Dane te s\u0105 gromadzone w naszym banku danych biologicznych CENTOGENE, kt\u00f3ry obejmuje ponad 800 000 pacjent\u00f3w z ponad 120 bardzo zr\u00f3\u017cnicowanych kraj\u00f3w, z czego ponad 70% to osoby pochodzenia pozaeuropejskiego. Do tej pory bank danych biologicznych CENTOGENE przyczyni\u0142 si\u0119 do wygenerowania nowatorskich spostrze\u017ce\u0144 dla ponad 285 recenzowanych publikacji.<\/p>\n

Przek\u0142adaj\u0105c nasze dane i wiedz\u0119 specjalistyczn\u0105 na konkretne wnioski, wsparli\u015bmy ponad 50 projekt\u00f3w wsp\u00f3\u0142pracy z partnerami farmaceutycznymi. Wsp\u00f3lnie przyspieszamy i ograniczamy ryzyko zwi\u0105zane z odkrywaniem, rozwojem i komercjalizacj\u0105 lek\u00f3w w zakresie bada\u0144 przesiewowych lek\u00f3w docelowych, bada\u0144 klinicznych, dost\u0119pu do rynku i ekspansji, a tak\u017ce oferujemy licencje CENTOGENE Biodata i raporty Insight Reports, aby umo\u017cliwi\u0107 \u015bwiatu wyleczenie ze wszystkich chor\u00f3b rzadkich i neurodegeneracyjnych.<\/p>\n

Aby dowiedzie\u0107 si\u0119 wi\u0119cej o naszych produktach, ofercie i celach ukierunkowanych na pacjent\u00f3w, odwied\u017a stron\u0119 www.centogene.com<\/a> i \u015bled\u017a nas na LinkedIn<\/a>.<\/p>\n

O\u015bwiadczenia prognostyczne<\/h3>\n

Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprojektowa\u0107\u201d, \u201cplanowa\u0107\u201d, \u201cma na celu\u201d, \u201cjest ustalony\u201d, \u201cpotencjalny\u201d, \u201cprzewidywa\u0107\u201d, \u201cobiektywny\u201d i podobne wyra\u017cenia oraz czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, lub ich formy przecz\u0105ce, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Do takich ryzyk i niepewno\u015bci nale\u017c\u0105 m.in. negatywne warunki ekonomiczne i geopolityczne oraz niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presja wynikaj\u0105ca ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w (FDA), zmiany w strukturze naszych klient\u00f3w i partner\u00f3w oraz ich praktykach zamawiania naszych produkt\u00f3w i rozwi\u0105za\u0144, nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem, realizacji naszej strategii biznesowej i nawi\u0105zywania nowych relacji z klientami, nasze uzale\u017cnienie od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasze uzale\u017cnienie od kluczowego personelu, nasze uzale\u017cnienie od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasza zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze ci\u0105g\u0142e przestrzeganie postanowie\u0144 umownych zwi\u0105zanych z instrumentami finansowymi, nasze zapotrzebowanie na dodatkowe finansowanie i nasza zdolno\u015b\u0107 do kontynuowania dzia\u0142alno\u015bci lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w Formularzu 20-F z\u0142o\u017conym przez CENTOGENE 16 maja 2023 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego publikacji, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n

KONTAKT<\/h5>\n

CENTOGENE 
Melissa Hall
Komunikacja korporacyjna
Press@centogene.com<\/a><\/p>\n

Lennart Streibel
Relacje inwestorskie
IR@centogene.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CENTOGENE i Fundacja Michaela J. Foxa og\u0142aszaj\u0105 projekt badawczy maj\u0105cy na celu weryfikacj\u0119 genetycznych czynnik\u00f3w ryzyka choroby Parkinsona za pomoc\u0105 multiomiki<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2181","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-23T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics\",\"datePublished\":\"2024-01-23T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/\"},\"wordCount\":1243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/\",\"name\":\"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2024-01-23T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE","og_description":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics","og_url":"https:\/\/www.centogene.com\/pl\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/","og_site_name":"CENTOGENE","article_published_time":"2024-01-23T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics","datePublished":"2024-01-23T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/"},"wordCount":1243,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/","url":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/","name":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2024-01-23T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-and-the-michael-j-fox-foundation-announce-research-project-to-validate-genetic-risk-factors-of-parkinsons-disease-using-multiomics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson\u2019s Disease Using Multiomics"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2181"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2181\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}